Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ABBV-932

Other · developed by AbbVie

Phase 2 Most advanced trial
ABBV Developer
1 Registered trials

What is ABBV-932?

ABBV-932 is an investigational drug studied in Bipolar I or II Disorder.

At a glance

Drug type
Other
Therapy area
Psychiatry
Developer
AbbVie (ABBV)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07220460 Phase 2 Bipolar I or II Disorder Active not recruiting ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Bipolar I or II Disorder

More from AbbVie

Adalimumab FDA approved Atogepant FDA approved Pivekimab Sunirine FDA approved Risankizumab FDA approved Telisotuzumab Vedotin FDA approved Upadacitinib FDA approved Venetoclax FDA approved ABBV-1042 Phase 1 ABBV-291 Phase 1 ABBV-295 Phase 2 ABBV-313 Phase 1 ABBV-324 Phase 1

Follow ABBV, the company behind ABBV-932

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.